WW International, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 30, 2023 (52 weeks). The filing was signed February 28, 2024. This is an annual report; unaudited fourth-quarter results are also disclosed.
Business context and reporting period
WW is a subscription-based weight-health company offering digital programs and workshops, plus WeightWatchers Clinic, a telehealth clinical subscription business acquired through the purchase of Sequence on April 10, 2023. At year-end, the company reported approximately 3.8 million subscribers: 3.1 million Digital, 0.7 million Workshops + Digital, and 66,600 Clinical. The company wound down its lower-margin consumer-products business at the end of FY2023. FY2023 reporting used North America and International segments; beginning in FY2024, the company moved to one reportable segment.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $889.6 million | $1,039.8 million |
| Subscription revenue | $822.8 million | $919.1 million |
| Gross profit / margin | $529.3 million / 59.5% | $621.4 million / 59.8% |
| Operating income (loss) | $22.3 million | $(284.0) million |
| Net loss | $(112.3) million | $(256.9) million |
| Diluted loss per share | $(1.46) | $(3.65) |
| Cash from operating activities | $6.7 million | $76.6 million |
Revenue fell 14.5% year over year, mainly from lower Digital subscriptions and the consumer-products wind-down. Clinical contributed $30.5 million in subscription revenue after the acquisition. End-of-period subscribers increased 7.1%, while total paid weeks declined 3.9%. North America revenue fell 12.3%; International revenue fell 19.6%.
Reported operating income improved from the prior-year loss, which included $396.7 million of franchise-rights and goodwill impairments. On the company’s non-GAAP adjusted basis, operating income was $89.5 million (10.1% margin), versus $152.5 million (14.7%) in FY2022; Adjusted EBITDAS was $146.4 million versus $206.1 million. These measures exclude specified restructuring, acquisition and impairment items.
Interest expense rose 18.2% to $95.9 million. The FY2023 tax provision was $38.6 million, including a substantial valuation-allowance charge; the company reported a full valuation allowance against U.S. deferred tax assets. The effective tax rate was (52.5%), making tax effects a significant contributor to the net loss.
Cash and cash equivalents were $109.4 million at year-end, down from $178.3 million. Current assets were $179.5 million and current liabilities $205.5 million; working capital excluding cash was a deficit of $135.4 million. Investing activities used $74.7 million, including acquisition spending. The company says operating cash, cash on hand, available revolver capacity, and cost management should provide liquidity, while noting it may delay investment or reduce marketing if needed.
Total debt was $1.445 billion: a $945 million term loan due April 2028 and $500 million of 4.5% secured notes due April 2029. Net debt was $1.317 billion; net debt/Adjusted EBITDAS was 9.0x. The term loan was variable-rate, and $500 million was hedged with swaps. At year-end, the reported weighted-average debt rate including swaps was 6.53%. The company’s first-lien leverage ratio was 8.49x; it was consequently limited to borrowing no more than 35% of revolver commitments, or $61.3 million, at quarter-end until it meets the applicable ratio.
Material changes, outlook, risks, contingencies, and unusual items
- FY2023 restructuring charges were $53.7 million, with approximately $44.6 million of restructuring cash outlays during the year; management expected approximately $18.5 million of such outlays in FY2024. It did not expect further FY2024 charges under the 2023 plan.
- Sequence acquisition consideration was stated as $132 million, including cash installments due in April 2024 and April 2025, and shares issued. The company reported $8.6 million of acquisition transaction costs and $89.7 million of acquisition goodwill.
- The company revised previously issued FY2022 and FY2021 financial statements to correct accounting errors it deemed immaterial, primarily involving income taxes and other prior-period items. FY2022 net loss was revised to $256.9 million. Management and the auditor concluded the revisions did not make prior statements materially misstated.
- FY2023 unaudited fourth-quarter revenue was $206.0 million and net loss was $88.1 million, compared with revenue of $222.9 million and net loss of $35.8 million in the fourth quarter of FY2022.
- No numerical FY2024 revenue or earnings guidance is provided in the supplied filing text. Management emphasizes subscriber recruitment and retention, cost focus, and execution of the Clinical strategy. Recruitment is seasonal, typically strongest in the first quarter.
- Key risks include competition from weight-loss medications and telehealth providers, pressure on subscriber retention and the Workshops + Digital business, medication supply constraints, high leverage and variable interest rates, limited revolver access, and complex healthcare, telehealth, privacy, and prescribing regulation. Management also identifies acquisition-integration, cybersecurity, foreign-exchange, macroeconomic, and impairment risks.
- The company recorded $3.6 million of goodwill impairment and a small franchise-rights impairment in FY2023 after a strategic-priority shift. It recorded $12.7 million of studio lease-closure charges. Management reported effective disclosure controls and internal control over financial reporting; the auditor gave an unqualified opinion on the financial statements and internal controls.
- An IRS penalty assessment related to Affordable Care Act reporting is under appeal. The company says it does not believe it has liability; the IRS tax lien is currently limited to certain refunds. Management says ordinary-course litigation is not expected to have a material adverse effect, but outcomes remain uncertain.
Most important facts for investors to verify
- Whether subscriber recruitment and retention stabilize, particularly in Digital and Workshops + Digital, and whether Clinical growth offsets declines elsewhere.
- Whether operating cash flow improves sufficiently to fund debt service, acquisition installments, and business investment; verify actual usable revolver capacity against the $61.3 million quarter-end limit.
- Debt costs and covenant headroom, including the impact of variable rates and the expiration of $500 million of interest-rate swaps in March 2024.
- Sequence’s subsequent revenue, subscriber growth, cash requirements, integration progress, and regulatory compliance.
- The recoverability of U.S. franchise-rights value and deferred tax assets, along with any future impairment or valuation-allowance changes.
- The final outcome of the IRS appeal and any material healthcare, privacy, prescribing, or other legal and regulatory proceedings.